Investing.com - Financial Markets Worldwide

Korean Drug Co Ltd (014570)

KOSDAQ
Currency in KRW
4,680
0(0.00%)
Closed·

014570 Financial Summary

Key Ratios

P/E Ratio118.14
Price/Book0.69
Debt / Equity0.09%
Return on Equity0.57%
Dividend Yield3.42%
EBITDA6.17B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa66,789.374,465.7379,984.0681,374.9873,001.42
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa28,689.4731,065.3434,517.1437,349.9434,401.15
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa11,039.3311,266.1914,329.026,720.294,104.71
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa7,359.659,042.3211,808.84-4,916.772,995.11
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa83,344.7688,612.6194,516.3689,709.0588,887.3
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa9,771.210,329.037,411.79,902.157,210.11
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa70,870.7976,689.984,712.6377,090.0878,106
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa9,411.466,243.37-2,708.727,388.433,629.5
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa12,330.088,805.865,912.57-1,998.54,868.69
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa-10,290.1-8,254.37-5,401.4212,273.73-10,888.77
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa-1,161.42-2,789.22-1,906.14-2,005.26-1,572.64
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa797.4-2,226.78-1,415.348,262.88-7,585.82
* In Millions of KRW (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 41.60%
Dividend Yield
3.42%
Industry Median 0.93%
Annualised payout
160.00
Paid annually
5-Years Growth
-
Growth Streak
Unlock

Earnings

Latest Release
May 15, 2025
EPS / Forecast
75.41 / --
Revenue / Forecast
13.09B / --
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Korean Drug's earnings for the latest quarter?

The Korean Drug EPS (TTM) is 41.60. Korean Drug reported sales of 13,086.47, net income of 801.61, and EPS of 75.41 for the latest quarter.

What was Korean Drug's net income for the latest quarter?

Korean Drug's net income for the latest quarter was 801.61.

How did Korean Drug's performance compare year-over-year in the latest quarter?

The company's revenue moved from 17,704.06 in the previous quarter to 13,086.47 in the latest quarter, and net income moved from -1,933.06 to 801.61 compared to the previous quarter.

What is Korean Drug's net profit margin on a TTM basis?

Korean Drug's trailing twelve months (TTM) net profit margin is 4.10%.

How does Korean Drug's debt to equity ratio compare to industry standards?

Korean Drug's total debt-to-equity ratio is 0.09%.

What is Korean Drug's return on investment on a TTM basis?

Korean Drug's trailing twelve months (TTM) return on investment (ROI) is 0.57%.

Did Korean Drug gain or lose cash last quarter?

In the latest quarter, Korean Drug's net change in cash was 1,745.22 million.

What were Korean Drug's total assets and liabilities in the latest quarter?

As of the latest quarter, Korean Drug reported total assets of 90,893.70 million and total liabilities of 10,264.09 million.

How has Korean Drug's total revenue grown this year?

Korean Drug's total revenue was 17,704.06 in the previous quarter and 13,086.47 in the latest quarter.

What is Korean Drug's gross margin on a TTM basis?

Korean Drug's trailing twelve months (TTM) gross margin is 47.05%.

What was Korean Drug's revenue per share for the latest quarter?

Korean Drug's revenue per share for the latest quarter was 14,080.43.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.